Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

180
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
180
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

8.5K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

164
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
164
Disorders of Hemostasis01:24

Disorders of Hemostasis

915
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
915

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions.

Arthritis care & research·2025
Same author

Predictors of Mortality in Antiphospholipid Antibody-Positive Patients: Prospective Results From Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository.

Arthritis care & research·2025
Same author

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.

Arthritis care & research·2024
Same author

Rethinking antiphospholipid syndrome to guide future management and research.

Nature reviews. Rheumatology·2024
Same author

Persistent Moderate-to-High Levels of Isolated Anticardiolipin Antibody IgA or Anti-β<sub>2</sub>-Glycoprotein-I IgA Isotypes: Do They Have Any Clinical Relevance?

Turkish journal of haematology : official journal of Turkish Society of Haematology·2024
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2024

Related Experiment Video

Updated: Jul 4, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

559

Antiphospholipid Syndrome: To Classify or Not to Classify?

Doruk Erkan1

  • 1Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, USA

Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology
|January 29, 2024
PubMed
Summary
This summary is machine-generated.

New 2023 classification criteria for Antiphospholipid Syndrome (APS) offer higher specificity for diagnosing this autoimmune disorder. This commentary guides their appropriate use in clinical practice and research.

Keywords:
Antiphospholipid syndromeClassification criteriaAntiphospholipid antibodies

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

382
Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS

Published on: October 7, 2009

27.0K

Related Experiment Videos

Last Updated: Jul 4, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

559
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

382
Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS

Published on: October 7, 2009

27.0K

Area of Science:

  • Rheumatology
  • Immunology
  • Autoimmune Diseases

Background:

  • Antiphospholipid syndrome (APS) is a systemic autoimmune disorder.
  • APS is characterized by thrombosis, pregnancy morbidity, and non-thrombotic manifestations.
  • Existing classification criteria have limitations.

Purpose of the Study:

  • To discuss the appropriate use of the 2023 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) APS classification criteria.
  • To demonstrate the application of the new criteria in case scenarios.

Main Methods:

  • Review of the 2023 ACR/EULAR APS classification criteria.
  • Analysis of case scenarios to illustrate criteria application.

Main Results:

  • The 2023 ACR/EULAR criteria demonstrate significantly higher specificity than previous criteria.
  • The new criteria reflect current understanding and research directions in APS.

Conclusions:

  • The 2023 ACR/EULAR criteria provide a refined foundation for APS diagnosis and research.
  • Understanding the appropriate application of these criteria is crucial for clinical practice.